227 related articles for article (PubMed ID: 31891807)
1. The potential clinical benefit of targeting androgen receptor (AR) in estrogen-receptor positive breast cancer cells treated with Exemestane.
Amaral C; Augusto TV; Almada M; Cunha SC; Correia-da-Silva G; Teixeira N
Biochim Biophys Acta Mol Basis Dis; 2020 May; 1866(5):165661. PubMed ID: 31891807
[TBL] [Abstract][Full Text] [Related]
2. Differential biological effects of aromatase inhibitors: Apoptosis, autophagy, senescence and modulation of the hormonal status in breast cancer cells.
Augusto TV; Amaral C; Almeida CF; Teixeira N; Correia-da-Silva G
Mol Cell Endocrinol; 2021 Nov; 537():111426. PubMed ID: 34391846
[TBL] [Abstract][Full Text] [Related]
3. Hormone-dependent breast cancer: Targeting autophagy and PI3K overcomes Exemestane-acquired resistance.
Amaral C; Augusto TV; Tavares-da-Silva E; Roleira FMF; Correia-da-Silva G; Teixeira N
J Steroid Biochem Mol Biol; 2018 Oct; 183():51-61. PubMed ID: 29791862
[TBL] [Abstract][Full Text] [Related]
4. Bicalutamide plus Aromatase Inhibitor in Patients with Estrogen Receptor-Positive/Androgen Receptor-Positive Advanced Breast Cancer.
Lu Q; Xia W; Lee K; Zhang J; Yuan H; Yuan Z; Shi Y; Wang S; Xu F
Oncologist; 2020 Jan; 25(1):21-e15. PubMed ID: 31434793
[TBL] [Abstract][Full Text] [Related]
5. Androgen Receptor Expression and Bicalutamide Antagonize Androgen Receptor Inhibit β-Catenin Transcription Complex in Estrogen Receptor-Negative Breast Cancer.
Huang R; Han J; Liang X; Sun S; Jiang Y; Xia B; Niu M; Li D; Zhang J; Wang S; Wei W; Liu Q; Zheng W; Zhang G; Song Y; Panga D
Cell Physiol Biochem; 2017; 43(6):2212-2225. PubMed ID: 29069648
[TBL] [Abstract][Full Text] [Related]
6. AR collaborates with ERα in aromatase inhibitor-resistant breast cancer.
Rechoum Y; Rovito D; Iacopetta D; Barone I; Andò S; Weigel NL; O'Malley BW; Brown PH; Fuqua SA
Breast Cancer Res Treat; 2014 Oct; 147(3):473-85. PubMed ID: 25178514
[TBL] [Abstract][Full Text] [Related]
7. Effects of aromatase inhibitors on human osteoblast and osteoblast-like cells: a possible androgenic bone protective effects induced by exemestane.
Miki Y; Suzuki T; Hatori M; Igarashi K; Aisaki KI; Kanno J; Nakamura Y; Uzuki M; Sawai T; Sasano H
Bone; 2007 Apr; 40(4):876-87. PubMed ID: 17254854
[TBL] [Abstract][Full Text] [Related]
8. An Exemestane Derivative, Oxymestane-D1, as a New Multi-Target Steroidal Aromatase Inhibitor for Estrogen Receptor-Positive (ER
Amaral C; Correia-da-Silva G; Almeida CF; Valente MJ; Varela C; Tavares-da-Silva E; Vinggaard AM; Teixeira N; Roleira FMF
Molecules; 2023 Jan; 28(2):. PubMed ID: 36677847
[TBL] [Abstract][Full Text] [Related]
9. Characterization of the weak estrogen receptor alpha agonistic activity of exemestane.
Masri S; Lui K; Phung S; Ye J; Zhou D; Wang X; Chen S
Breast Cancer Res Treat; 2009 Aug; 116(3):461-70. PubMed ID: 18677558
[TBL] [Abstract][Full Text] [Related]
10. Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide.
Cochrane DR; Bernales S; Jacobsen BM; Cittelly DM; Howe EN; D'Amato NC; Spoelstra NS; Edgerton SM; Jean A; Guerrero J; Gómez F; Medicherla S; Alfaro IE; McCullagh E; Jedlicka P; Torkko KC; Thor AD; Elias AD; Protter AA; Richer JK
Breast Cancer Res; 2014 Jan; 16(1):R7. PubMed ID: 24451109
[TBL] [Abstract][Full Text] [Related]
11. Molecular characterization of aromatase inhibitor-resistant, tamoxifen-resistant and LTEDaro cell lines.
Masri S; Phung S; Wang X; Chen S
J Steroid Biochem Mol Biol; 2010 Feb; 118(4-5):277-82. PubMed ID: 19897035
[TBL] [Abstract][Full Text] [Related]
12. New cell culture model for aromatase inhibitor-resistant breast cancer shows sensitivity to fulvestrant treatment and cross-resistance between letrozole and exemestane.
Hole S; Pedersen AM; Hansen SK; Lundqvist J; Yde CW; Lykkesfeldt AE
Int J Oncol; 2015 Apr; 46(4):1481-90. PubMed ID: 25625755
[TBL] [Abstract][Full Text] [Related]
13. Anti-tumor efficacy of new 7α-substituted androstanes as aromatase inhibitors in hormone-sensitive and resistant breast cancer cells.
Amaral C; Varela CL; Maurício J; Sobral AF; Costa SC; Roleira FMF; Tavares-da-Silva EJ; Correia-da-Silva G; Teixeira N
J Steroid Biochem Mol Biol; 2017 Jul; 171():218-228. PubMed ID: 28396197
[TBL] [Abstract][Full Text] [Related]
14. Effects of new C6-substituted steroidal aromatase inhibitors in hormone-sensitive breast cancer cells: Cell death mechanisms and modulation of estrogen and androgen receptors.
Augusto TV; Amaral C; Varela CL; Bernardo F; da Silva ET; Roleira FFM; Costa S; Teixeira N; Correia-da-Silva G
J Steroid Biochem Mol Biol; 2019 Dec; 195():105486. PubMed ID: 31557516
[TBL] [Abstract][Full Text] [Related]
15. Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic Breast Cancer.
Gucalp A; Tolaney S; Isakoff SJ; Ingle JN; Liu MC; Carey LA; Blackwell K; Rugo H; Nabell L; Forero A; Stearns V; Doane AS; Danso M; Moynahan ME; Momen LF; Gonzalez JM; Akhtar A; Giri DD; Patil S; Feigin KN; Hudis CA; Traina TA;
Clin Cancer Res; 2013 Oct; 19(19):5505-12. PubMed ID: 23965901
[TBL] [Abstract][Full Text] [Related]
16.
Bezerra PHA; Amaral C; Almeida CF; Correia-da-Silva G; Torqueti MR; Teixeira N
Molecules; 2023 Jun; 28(13):. PubMed ID: 37446555
[TBL] [Abstract][Full Text] [Related]
17. The growth response to androgen receptor signaling in ERα-negative human breast cells is dependent on p21 and mediated by MAPK activation.
Garay JP; Karakas B; Abukhdeir AM; Cosgrove DP; Gustin JP; Higgins MJ; Konishi H; Konishi Y; Lauring J; Mohseni M; Wang GM; Jelovac D; Weeraratna A; Sherman Baust CA; Morin PJ; Toubaji A; Meeker A; De Marzo AM; Lewis G; Subhawong A; Argani P; Park BH
Breast Cancer Res; 2012 Feb; 14(1):R27. PubMed ID: 22321971
[TBL] [Abstract][Full Text] [Related]
18. Niclosamide and Bicalutamide Combination Treatment Overcomes Enzalutamide- and Bicalutamide-Resistant Prostate Cancer.
Liu C; Armstrong CM; Lou W; Lombard AP; Cucchiara V; Gu X; Yang JC; Nadiminty N; Pan CX; Evans CP; Gao AC
Mol Cancer Ther; 2017 Aug; 16(8):1521-1530. PubMed ID: 28500234
[TBL] [Abstract][Full Text] [Related]
19. Overcoming aromatase inhibitor resistance in breast cancer: possible mechanisms and clinical applications.
Hanamura T; Hayashi SI
Breast Cancer; 2018 Jul; 25(4):379-391. PubMed ID: 28389808
[TBL] [Abstract][Full Text] [Related]
20. Androgen metabolite-dependent growth of hormone receptor-positive breast cancer as a possible aromatase inhibitor-resistance mechanism.
Hanamura T; Niwa T; Nishikawa S; Konno H; Gohno T; Tazawa C; Kobayashi Y; Kurosumi M; Takei H; Yamaguchi Y; Ito K; Hayashi S
Breast Cancer Res Treat; 2013 Jun; 139(3):731-40. PubMed ID: 23780684
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
